FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Released May 30, 2017.